Harpoon Therapeutics is an immuno-oncology company which uses a proprietary technology platform focused on T cell engagement to discover and develop novel biologics for the treatment of cancer and other diseases. The Company has designed a novel antibody-based drug discovery platform called TriTAC™ that unleashes the target cell killing properties of a patient’s own immune system through T cell activation.TriTAC™ antibodies are designed to simultaneously bind to cancer cells and T cells, causing the attached T cells to release toxic factors leading to destruction of the attached target cell. In addition, TriTAC™ antibodies are engineered to bind to human serum albumin which allows for less frequent dosing, and their relatively small size allows for improved penetration into tumor tissue.